Patents by Inventor Adolfo Garcia-Sastre
Adolfo Garcia-Sastre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11865173Abstract: Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.Type: GrantFiled: January 24, 2022Date of Patent: January 9, 2024Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter Palese, Adolfo Garcia-Sastre, Megan Ermler, Florian Krammer
-
Publication number: 20230373997Abstract: Provided herein are lipidated imidazoquinoline compounds and compositions comprising such compounds. The lipidated imidazoquinoline compounds may be used as an adjuvant to enhance to immune response elicited by an antigen of interest. Accordingly, N also provided herein are methods for enhancing the immune response of an antigen of interest in a subject, comprising administering h to the subject an antigen of interest with a lipidated imidazoquinoline compound described herein in an immunogenic composition, or administering to the subject a composition comprising a lipidated imidazoquinoline compound described herein in combination with N (e.g., prior to, concurrently, or subsequently) the administration of an immunogenic composition comprising an antigen of interest to the subject.Type: ApplicationFiled: October 7, 2021Publication date: November 23, 2023Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, UNIVERSITEIT GENTInventors: Adolfo GARCIA-SASTRE, Michael SCHOTSAERT, Angela CHOI, Bruno DE GEEST, Jana DE VRIEZE
-
Publication number: 20230310583Abstract: Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotid sequence encoding a SARS-CoV-2 spike protein or nucleocapsid protein. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 spike protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against SARS-CoV-2 as well as the prevention of COVID-19.Type: ApplicationFiled: May 6, 2021Publication date: October 5, 2023Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Weina SUN, Florian KRAMMER, Adolfo GARCIA-SASTRE, Peter PALESE
-
Publication number: 20230286934Abstract: Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering a compound of Formula (I), or a salt thereof, or a composition thereof to a subject (e.g., a human subject). Also provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108110 or a composition thereof to a subject (e.g., a human subject). In addition, provided herein are methods for treating a virus (e.g., an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108600 or a composition thereof to a subject (e.g., a human subject).Type: ApplicationFiled: June 8, 2021Publication date: September 14, 2023Inventors: Premkumar Reddy, Adolfo Garcia-Sastre, Ramana M.V. Reddy, Kris White
-
Publication number: 20230248680Abstract: Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering Rigosertib or a composition thereof to a subject (e.g., a human subject).Type: ApplicationFiled: May 28, 2021Publication date: August 10, 2023Inventors: Premkumar Reddy, Kris White, M.V. Ramana Reddy, Adolfo Garcia-Sastre
-
Publication number: 20230226171Abstract: An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and/or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-CoV-2 exogenous nucleotide sequence inserted,Type: ApplicationFiled: February 22, 2021Publication date: July 20, 2023Inventors: Bernardo LOZANO-DUBERNARD, Ernesto SOTO-PRIANTE, David SARFATI-MIZRAHI, Felipa CASTRO-PERALTA, Georgina PAZ-DE LA ROSA, Peter PALESE, Adolfo GARCIA-SASTRE, Florian KRAMMER, Weina SUN
-
Publication number: 20230181715Abstract: The present invention relates to compositions and methods for inducing an immune response against influenza virus in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding at least one influenza virus antigen, such as a hemagglutinin antigen or a fragment thereof, neuraminidase antigen or a fragment thereof, nucleoprotein antigen or a fragment thereof, matrix protein 1 antigen or a fragment thereof, or matrix-2 ion channel antigen or a fragment thereof.Type: ApplicationFiled: March 31, 2021Publication date: June 15, 2023Inventors: Norbert Pardi, Drew Weissman, Raffael Nachbagauer, Scott Hensley, Peter Palese, Florian Krammer, Adolfo Garcia-Sastre, Alec W. Freyn
-
Publication number: 20230151070Abstract: In one aspect, provided herein are methods for treating cancer in a subject, comprising administering to a subject an oncolytic virus (e.g., an avian paramyxovirus (AMPV)) and a vascular endothelial growth factor (VEGF)-C agent, a VEGF-D agent, or a VEGF receptor (VEGFR)-3-activating agent. In another aspect, provided herein are oncolytic viruses (e.g. APMV) comprising a genome, wherein the genome comprises a transgene that comprises a nucleotide sequence encoding a VEGF-C agent, a VEGF-D agent or a VEGF receptor (VEGFR)-3-activating agent. In another aspect, provided herein are methods for treating cancer, comprising administering to a subject an oncolytic virus (e.g. APMV), wherein the oncolytic virus comprises a genome that comprises a transgene comprising a nucleotide sequence encoding a VEGF-C agent, a VEGF-D agent, or a VEGF receptor (VEGFR)-3-activating agent.Type: ApplicationFiled: February 26, 2021Publication date: May 18, 2023Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Mihaela SKOBE, Andrew Kenneth EDWARDS, Ruben FERNANDEZ-RODRIGUEZ, Adolfo GARCIA-SASTRE, Ignacio MENA, Sara CUADRADO CASTAÑO
-
Publication number: 20220403358Abstract: In one aspect, provided herein are recombinant neuraminidases comprising an ectodomain of influenza virus neuraminidase with amino acid substitutions or insertions of cysteines in the stalk domain to generate a more stable, tetrameric influenza virus neuraminidase. In specific embodiments, the influenza virus neuraminidase further comprises influenza virus neuraminidase transmembrane and cytoplasmic domains. In another aspect, provided herein are recombinant neuraminidase comprising a globular head domain of influenza virus neuraminidase and a tetramerization domain, wherein the recombinant neuraminidase lacks influenza virus neuraminidase stalk, transmembrane and cytoplasmic domains. In another aspect, provided herein are methods of immunizing against influenza virus using such recombinant neuraminidases or compositions thereof.Type: ApplicationFiled: October 21, 2020Publication date: December 22, 2022Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter PALESE, Adolfo GARCIA-SASTRE, Florian KRAMMER
-
Publication number: 20220363736Abstract: Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.Type: ApplicationFiled: January 5, 2022Publication date: November 17, 2022Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter PALESE, Florian KRAMMER, Teddy John WOHLBOLD, Adolfo GARCIA-SASTRE
-
Publication number: 20220257749Abstract: Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.Type: ApplicationFiled: January 24, 2022Publication date: August 18, 2022Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter PALESE, Adolfo GARCIA-SASTRE, Megan ERMLER, Florian KRAMMER
-
Publication number: 20220249652Abstract: In one aspect, provided herein are mutated influenza virus neuraminidase polypeptides, wherein the mutated influenza virus neuraminidase polypeptides comprise a first cytoplasmic domain, a first transmembrane domain, a first stalk domain, and a first globular head domain of a first neuraminidase of a first influenza virus with an insertion of 15 to 45 or 1 to 50 amino acid residues in the first stalk domain of the first neuraminidase. In another aspect, provided herein is an influenza virus comprising such a mutated influenza virus neuraminidase polypeptide, a genome comprising a nucleotide sequence encoding such a mutated influenza virus neuraminidase polypeptide or both. In another aspect, provided herein is an immunogenic composition comprising such an influenza virus, and optionally an adjuvant.Type: ApplicationFiled: June 25, 2020Publication date: August 11, 2022Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter PALESE, Adolfo GARCIA-SASTRE, Florian KRAMMER, Felix BRÖCKER, Allen ZHENG, Weina SUN
-
Publication number: 20220241358Abstract: In one aspect, provided herein are naturally occurring and recombinantly produced avian paramyxovirus (APMV) (e.g., an APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9 strain) and uses of such APMV for the treatment of cancer. In particular, provided herein are methods for treating cancer comprising administering a naturally occurring or recombinantly produced APMV-4 strain to a subject in need thereof. In another aspect, provided herein are recombinant APMV comprising a packaged genome, wherein the packaged genome comprises a transgene. In particular, described herein are recombinant APMV (e g., APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9). In another aspect, provided herein are methods for treating cancer comprising administering a recombinant APMV (e g., APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9) to a subject in need thereof, wherein the recombinant APMV comprises a packaged genome comprising a transgene.Type: ApplicationFiled: November 16, 2021Publication date: August 4, 2022Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Adolfo GARCIA-SASTRE, Peter PALESE, Sara CUADRADO CASTAÑO
-
Publication number: 20220153873Abstract: Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.Type: ApplicationFiled: April 23, 2020Publication date: May 19, 2022Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Florian KRAMMER, Teddy John WOHLBOLD, Adolfo GARCIA-SASTRE, Peter PALESE
-
Patent number: 11266734Abstract: Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.Type: GrantFiled: June 14, 2017Date of Patent: March 8, 2022Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter Palese, Adolfo Garcia-Sastre, Megan Ermler, Florian Krammer
-
Patent number: 11254733Abstract: Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.Type: GrantFiled: April 6, 2018Date of Patent: February 22, 2022Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter Palese, Florian Krammer, Teddy John Wohlbold, Adolfo Garcia-Sastre
-
Publication number: 20210260179Abstract: In one aspect, provided herein is a mosaic influenza virus hemagglutinin (HA) polypeptide comprising an influenza A virus HA ectodomain of an influenza A virus strain HA, wherein the HA ectodomain comprises an HA stem domain of the influenza A virus strain HA and an HA globular head domain of the influenza A virus strain HA, wherein the HA globular head domain of the influenza A virus strain HA has been engineered to comprise one or more amino acid substitutions in one, two, three, four or all of the antigenic sites. In another aspect, provided herein are immunogenic compositions comprising such a mosaic influenza virus HA polypeptide or an influenza A virus comprising such a mosaic influenza virus HA polypeptide. In yet another aspect, provided herein are methods for immunizing a subject against an influenza A vims in a subject comprising administering such an immunogenic composition to the subject.Type: ApplicationFiled: June 20, 2019Publication date: August 26, 2021Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Adolfo GARCIA-SASTRE, Peter PALESE, Florian KRAMMER, Felix BRÖCKER, Weina SUN
-
Publication number: 20210198323Abstract: Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a respiratory syncytial virus (“RSV”) F protein or human metapneumovirus (“hMPV”) F protein. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises (i) an RSV F protein ectodomain and NDV F protein transmembrane and cytoplasmic domains; or (ii) an hMPV F protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against RSV or hMPV as well as the prevention of RSV disease or hMPV disease.Type: ApplicationFiled: August 16, 2019Publication date: July 1, 2021Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Joan E. DURBIN, Russell K. DURBIN, Adolfo GARCIA-SASTRE, Ignacio MENA, Peter PALESE
-
Publication number: 20200297787Abstract: In one aspect, provided herein are naturally occurring and recombinantly produced avian paramyxovirus (APMV) (e.g., an APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9 strain) and uses of such APMV for the treatment of cancer. In particular, provided herein are methods for treating cancer comprising administering a naturally occurring or recombinantly produced APMV-4 strain to a subject in need thereof. In another aspect, provided herein are recombinant APMV comprising a packaged genome, wherein the packaged genome comprises a transgene. In particular, described herein are recombinant APMV (e g., APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9). In another aspect, provided herein are methods for treating cancer comprising administering a recombinant APMV (e g., APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9) to a subject in need thereof, wherein the recombinant APMV comprises a packaged genome comprising a transgene.Type: ApplicationFiled: July 12, 2019Publication date: September 24, 2020Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Adolfo GARCIA-SASTRE, Peter PALESE, Sara CUADRADO CASTAÑO
-
Patent number: 10736956Abstract: Provided herein are immunization regimens for inducing an immune response (e.g., an antibody response) against influenza virus. In specific aspects, the immunization regimens involve the administration of a chimeric hemagglutinin (HA), a headless HA or another influenza virus stem domain based construct (e.g., the HA stem domain or a fragment thereof) to a subject. In certain aspects, the immunization regimens also involve the administration of an influenza virus neuraminidase immunogen.Type: GrantFiled: January 22, 2016Date of Patent: August 11, 2020Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter Palese, Adolfo Garcia-Sastre, Florian Krammer